On May 26, 2026, India's CDSCO released revised Regulatory Guidelines for Sampling of Drugs, Cosmetics and Medical Devices by Drug Inspectors of Central and State Drug Authorities. The update strengthens post-market surveillance and regulatory enforcement by expanding reporting requirements for products identified as Not of Standard Quality (NSQ) or spurious.

The revised document supersedes the February 2024 version and largely keeps the existing structure, covering sampling plans, sample selection, sampling locations, sample quantities, timelines, database monitoring, NSQ and spurious alerts, and testing laboratories.